NCT07606625 Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment
| NCT ID | NCT07606625 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, Berkeley |
| Condition | Dry Eye |
| Study Type | INTERVENTIONAL |
| Enrollment | 65 participants |
| Start Date | 2026-03-06 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 65 participants in total. It began in 2026-03-06 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).
Eligibility Criteria
Inclusion Criteria: * Is 18 years of age and has full legal capacity to volunteer (no max age requirement) * Baseline Ocular Surface Disease Index (OSDI) \>13 * Has mild to moderate MGD * Has best corrected visual acuity of 20/40 or better * Has had an oculo-visual examination in the last two years * Is willing to continue other daily dry eye management regimen (e.g., warm compresses, and/or eyelid margin cleaning) * Is willing to discontinue other prescription medications for dry eye disease (DED) management * Is willing to stop any topical eye drops before all planned visits * Has read, understood, and completed the informed consent letter Exclusion Criteria: * Is participating in any other type of clinical or research study * Is currently pregnant, nursing, lactating, or planning a pregnancy * Is currently having \>50% blockage of Meibomian glands in more than two eyelids or significant atrophy (i.e., severe MGD) * Is currently using any topical ocular medications * Has chronic or currently active sinus related problems * Has blepharitis \> grade 1 * Has active ocular infections * Has a condition or in a situation which, in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation in the study * Has received Rx DED treatment within one week of enrollment * Has received any thermal or light-based DED treatment within 30 days of enrollment * Has significant corneal epithelial defects * Has abnormal eyelid anatomy * Has corneal neuropathic pain * Has chronic or recurrent epistaxis (nosebleeds), coagulation disorders, or other conditions that may have led to a clinically significant increased risk of bleeding * Has any intraocular surgery including trabeculectomy (MIGS, laser, or small incision glaucoma surgery allowed), extraocular surgery in either eye within 3 months, or refractive surgery within 12 months of enrollment * Has a known allergy to a product used in this study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07606625 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dry Eye. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07606625 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07606625 currently recruiting?
Yes, NCT07606625 is actively recruiting participants. Contact the research team at mlin@berkeley.edu for enrollment information.
Where is the NCT07606625 trial being conducted?
This trial is being conducted at Berkeley, United States.
Who is sponsoring the NCT07606625 clinical trial?
NCT07606625 is sponsored by University of California, Berkeley. The trial plans to enroll 65 participants.